Acromegaly: The disease, its impact on patients, and managing the burden of long-term treatment

International Journal of General Medicine

Volumn 6, Issue , 2013, Pages 31-38

  Adelman, Daphne T ^a   Liebert, Karen J P ^b   Nachtigall, Lisa B ^b   Lamerson, Michele ^c   Bakker, Bert ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c IPSEN   (France)

Author keywords

Acromegaly; Convenience; Diagnosis; Quality of life; Treatment

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR BLOCKING AGENT; OCTREOTIDE; PEGVISOMANT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACROMEGALY; AWARENESS; BIOCHEMISTRY; CARDIOVASCULAR RISK; CHOLECYSTITIS; CLINICAL FEATURE; COMORBIDITY; DELAYED DIAGNOSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG SELF ADMINISTRATION; EARLY DIAGNOSIS; FLU LIKE SYNDROME; GALLSTONE; GASTROINTESTINAL DISEASE; GROWTH HORMONE RELEASE; HEADACHE; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH PRACTITIONER; HORMONE DETERMINATION; HUMAN; HYPOPHYSIS ADENOMA; INDIVIDUALIZATION; INJECTION SITE REACTION; LONG TERM CARE; MEDICAL DECISION MAKING; MORTALITY; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PATIENT MONITORING; PATIENT SELECTION; PROFESSIONAL PRACTICE; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIOTHERAPY; REVIEW; STEREOTACTIC RADIOSURGERY; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT OUTCOME;

EID: 84874717906     PISSN: None     EISSN: 11787074     Source Type: Book Series    
DOI: 10.2147/IJGM.S38594     Document Type: Review

References (45)

1. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24): 2558-2573.
2. Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J. Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab. 2009; 23(5):555-574.
3. International Diabetes Federation (IDF). IDF Diabetes Atlas, 5th ed. Brussels: IDF; 2011.
4. Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A. Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab. 2008;93(6):2035-2041.
5. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011;17 Suppl 4:1-44.
6. Giustina A, Chanson P, Bronstein MD, et al; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-3148.
7. Melmed S, Colao A, Barkan A, et al; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-1517.
8. Davi' MV, Dalle Carbonare L, Giustina A, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol. 2008;159(5): 533-540.
9. Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008;14(22):3484-3489.
10. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3):301-342.
11. Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab. 2000;85(1): 168-174.
12. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN. Basal and glucose-suppressed GH levels less than 1microg/L in newly diagnosed acromegaly. Pituitary. 2003;6(4):175-180.
13. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical "cure'. Eur J Endocrinol. 2005;152(3):379-387.
14. Ipsen. Somatuline® Depot [prescribing information]. Silver Spring, MD: US Food and Drug Administration (FDA); 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022074s003lbl.pdf. Accessed September 28, 2012.
15. Novartis. Sandostatin® LAR Depot [prescribing information]. Silver Spring, MD: FDA; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021008s025lbl.pdf. Accessed September 28, 2012.
16. Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf). 2007;67(2): 282-289.
17. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol. 2006;64(2):209-214.
18. Mercado M, Borges F, Bouterfa H, et al; SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol. 2007;66(6):859-868.
19. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93(8):2957-2968.
20. Pzifer. Somavert® [prescribing information]. Silver Spring, MD: FDA; 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021106s031lbl.pdf. Accessed September 28, 2012.
21. Novartis. Parlodel® [prescribing information]. Silver Spring, MD: FDA; 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf. Accessed September 28, 2012.
22. Pfizer. Dostinex® [prescribing information]. Silver Spring, MD: FDA; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s012lbl.pdf. Accessed September 28, 2012.
23. Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab. 2011;96(7):1992-2003.
24. Petit JH, Biller BM, Coen JJ, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract. 2007;13(7): 726-734.
25. Jagannathan J, Sheehan JP, Pouratian N, Laws ER Jr, Steiner L, Vance ML. Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery. Neurosurgery. 2008;62(6):1262-1269; discussion 1262-1269.
26. Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg. 2007;106(5):833-838.
27. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. 2011;14(3):284-294.
28. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94(5): 1500-1508.
29. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab. 2005;90(6):3337-3341.
30. Webb SM, Badia X, Surinach NL; Spanish AcroQoL Study Group. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol. 2006;155(2):269-277.
31. Kauppinen-Mäkelin R, Sane T, Sintonen H, et al. Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab. 2006; 91(10):3891-3896.
32. Sievers C, Ising M, Pfister H, et al. Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age-and gender-matched controls. Eur J Endocrinol. 2009;160(3):367-373.
33. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab. 2005;90(5):2731-2739.
34. Wassenaar MJ, Biermasz NR, Kloppenburg M, et al. Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Horm IGF Res. 2010;20(3):226-233.
35. Lombardi G, Minuto F, Tamburrano G, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endrocrinol Invest. 2009; 32(3):202-209.
36. Ghigo E, Biller BM, Colao A, et al. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. J Endocrinol Invest. 2009;32(11):924-933.
37. Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93(10): 3853-3859.
38. Wexler T, Gunnell L, Omer Z, et al. Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab. 2009;94(7):2471-2477.
39. Miller KM, Wexler T, Fazeli P, et al. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab. 2010;95(2): 567-577.
40. Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol. 2006;155(6):831-837.
41. Novartis. Sandostatin® LAR Depot: nurse home injection program (NHIP) for eligible patients with acromegaly [web page on the Internet]. East Hanover, NJ: Novartis; nd. Available from: http://www.us.sandostatin.com/patient/disease/acromegaly/nhip.jsp. Accessed November 15, 2012.
42. Salvatori R, Nachtigall LB, Cook DM, et al; SALSA Study Group. Effectiveness of self-or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly. Pituitary. 2010;13(2):115-122.
43. Higham CE, Thomas JD, Bidlingmaier M, Drake WM, Trainer PJ. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol. 2009;161(1):21-25.
44. Harris AG, Daly AF. Treatment of acromegaly. In: Acromegaly and its management. Philadelphia, PA: Lippincott-Raven; 1996:49-68.
45. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am. 1992;21(3):597-614.